A Phase 3 interventional study of Oxycodone HCl controlled-release tablets in Pain, sponsored by Purdue Pharma LP. Completed at 47 sites in 8 countries. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2020-03-23.
Sponsored by Purdue Pharma LP (part of Knoa Pharma) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing oxycodone in Pain — 4 open to participants now, 5 under way, 1 of them phase 3. Oxycodone · Pain.
Among the 50 studies testing oxycodone in Pain, this one is the 12th largest by enrollment, is one of 3 that started in 2010, is one of 10 in phase 3, and was the 9th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →4 of the 50 studies testing oxycodone in Pain are open now, in 2 countries. Recruiting first, the newest first:
Kafrelsheikh University · Sites in Egypt
Ages 18–65
University of Florida · Sites in United States
Ages 45–85 · Healthy volunteers
University of Florida · Sites in United States
Ages 21–45 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 6 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 67 across the 50 interventional studies. Of the 37 that completed or were terminated, 13 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Purdue Pharma LP, one of the names counted as Knoa Pharma. Under that name alone:
Purdue Pharma LP is the lead sponsor of 58 studies on the registry; none are open to participants now.
13 studies in Pain by Knoa Pharma: none open now, none under way, none of them phase 3. Of 12 finished, 7 (58%) have results posted.
Among the 13 studies in Pain by Knoa Pharma, this one is the 7th largest by enrollment, is the only one that started in 2010, is one of 7 in phase 3, and was the 3rd registered.
Knoa Pharma’s Pain studies by the year they started, since 2001.
3 of the studies testing oxycodone in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05761860University of FloridaThe Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults | 2026-12 |
| NCT04218409University of FloridaOpioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination | 2026-12-31 |
| NCT05548582Johns Hopkins UniversityReduced Opioid Prescription After Laparoscopic Hysterectomy | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 50 studies testing oxycodone in Pain, from their registry updates:
Among Knoa Pharma’s 13 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the safety of oxycodone hydrochloride (HCl) controlled-release (CR) tablets in opioid tolerant pediatric patients aged 6 to 16 years, inclusive, with moderate to severe malignant and/or nonmalignant pain requiring opioid therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria include:
Other protocol-specific inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oxycodone hydrochloride (HCl) controlled-release (CR)
Drug: Oxycodone HCl controlled-release tablets
Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.
Also known as: OxyContin
The Number of Participants With Adverse Events as a Measure of Safety.
Safety assessments consisted of reports of AEs, physical examinations, clinical laboratory test results, vital signs measurements, pulse oximetry (SpO2), and somnolence assessments. Safety variables were summarized descriptively within age group for the safety population.
Time frame: Up to 4 weeks (during the study) and 7-10 days poststudy (safety follow-up assessment).
Pain Right Now Assessment by Patients Aged 6 to < 12 Years
Pain right now was assessed by patients aged 6 to \<12 years using the Faces of Pain Scale-Revised (FPS-R). The FPS-R is a horizontal row of 6 faces representing pain intensity, with "no hurt" at the far left and "hurts worst" at the far right; the 6 intensities are scored as 0, 2, 4, 6, 8, or 10 (the patient was not shown the numbers associated with the faces). A score of 0 means no pain, and a 10 means very much pain. Pain right now was assessed by the patient at screening; after the first dose; and, thereafter, twice daily during the AM and PM, approximately at the time of each (morning and evening) dose of oxycodone HCl CR tablets during the study treatment.
Time frame: Baseline to week 4
Pain Right Now Assessment by Patients Aged ≥ 12 to ≤ 16 Years
Pain right now was assessed by patients aged ≥ 12 to ≤ 16 years using the 100-mm visual analogue scale (VAS). The 100-mm VAS is a 100-mm line with 1 end marked "no pain" and the opposite end marked as "pain as bad as it could be." The patient was asked to make a mark on that line indicating his or her level of pain. The pain right now 100-mm VAS score was defined as the distance (in mm) from the "no pain" end to the patient's mark. The scale is measured on a 100 mm line: a 0 means no pain and bigger numbers indicate more pain. Pain right now was assessed by the patient at screening; after the first dose; and, thereafter, twice daily during the AM and PM, approximately at the time of each (morning and evening) dose of oxycodone HCl CR tablets during the study treatment.
Time frame: Baseline to week 4
Use of Supplemental Pain Medication
Supplemental opioid and nonopioid pain medications were permitted during the study as deemed appropriate by the investigator. The dose of supplemental analgesic medication allowed was at the discretion of the investigator and within appropriate dose ranges for age and weight.
Time frame: Baseline to week 4
Parent/ Caregiver-Assessed Global Impression of Change (PGIC)
The PGIC rating score variable was collected on a 7-point scale ranging from 1 to 7 (where 1 = very much improved; and 7 = very much worse). The PGIC is designed to assess overall satisfaction with the treatment. The number and percent of parent/caregivers reporting each category of PGIC response at the final visit was summarized for the safety population within age group.
Time frame: Baseline to week 4 or early discontinuation
Parent/ Caregiver Assessed Functional Disability Inventory (FDI) for Patients Aged 6 to < 12 Years
The FDI is a validated tool used to evaluate the degree to which children have reduced physical and psychosocial functioning because of their pain difficulties in the previous 2 weeks. The FDI comprises 15 items. Responses to each item were scored using a 5-point Likert scale. The individual scores are: (0) no trouble, (1) a little trouble, (2) some trouble, (3) a lot of trouble, and (4) impossible. A total score (ranging from 0 to 60) for the 15 items was calculated, with lower scores indicating less functional disability. The FDI was performed by the parent/ caregiver.
Time frame: Baseline to week 4
Parent/ Caregiver Assessed Functional Disability Inventory (FDI) for Patients Aged ≥ 12 to ≤ 16 Years
The FDI is a validated tool used to evaluate the degree to which children have reduced physical and psychosocial functioning because of their pain difficulties in the previous 2 weeks. The FDI comprises 15 items. Responses to each item were scored using a 5-point Likert scale. The individual scores are: (0) no trouble, (1) a little trouble, (2) some trouble, (3) a lot of trouble, and (4) impossible. A total score (ranging from 0 to 60) for the 15 items was calculated, with lower scores indicating less functional disability. The FDI was performed by the parent/ caregiver.
Time frame: Baseline to week 4
Pharmacokinetics (PK) Data of Oxycodone Hydrochloride Controlled-release Tablets
A population PK analysis using sparse plasma concentration data in pediatric patients was conducted. Empirical Bayes estimates were used to calculate individual PK parameters. PK parameters were calculated and reported for each individual patient's first and last dose. Cmax was taken as the maximum simulated oxycodone concentration over the dosing interval and Cmin was the simulated oxycodone concentration when time was equal to 12 hours. Steady-state Cmin and Cmax were derived from the accumulation ratio. The following PK parameters are presented: Cmin / Cmax (minimum / maximum concentration); Cmin,ss / Cmax,ss (Cmin / Cmax at steady state); CAVGss (average concentration at steady state).
Time frame: Day 1 - first dose [2-4 hrs post dose and 4-6 hrs post dose], week 4 - last dose [at pre-dose and at 2-4 hrs post dose]
Pharmacokinetics (PK) Data of Oxycodone Hydrochloride Controlled-release Tablets - AUCtau and AUCss
A population PK analysis using sparse plasma concentration data in pediatric patients was conducted. Empirical Bayes estimates were used to calculate individual PK parameters. PK parameters were calculated and reported for each individual patient's first and last dose. First-dose area under the concentration-time curve (AUC) was derived from the accumulation ratio. For all calculations, the dosing interval was assumed to be 12 hours. The following PK parameters are presented: AUCtau (area under the concentration-time curve from time zero to time equal to dosing interval); AUCss (AUC at steady state).
Time frame: Day 1 - first dose [2-4 hrs post dose and 4-6 hrs post dose], week 4 - last dose [at pre-dose and at 2-4 hrs post dose]
Pharmacokinetics (PK) Data of Oxycodone Hydrochloride Controlled-release Tablets - Time to Maximum Concentration (Tmax)
A population PK analysis using sparse plasma concentration data in pediatric patients was conducted. Empirical Bayes estimates were used to calculate individual PK parameters. PK parameters were calculated and reported for each individual patient's first and last dose.
Time frame: Day 1 - first dose [2-4 hrs post dose and 4-6 hrs post dose], week 4 - last dose [at pre-dose and at 2-4 hrs post dose]
Pharmacokinetics (PK) Data of Oxycodone Hydrochloride Controlled-release Tablets - Accumulation Ratio
A population PK analysis using sparse plasma concentration data in pediatric patients was conducted. Empirical Bayes estimates were used to calculate individual PK parameters. PK parameters were calculated and reported for each individual patient's first and last dose. The accumulation ratio is used to derive steady-state Cmin and Cmax and first-dose area under the concentration-time curve (AUCtau).
Time frame: Day 1 - first dose [2-4 hrs post dose and 4-6 hrs post dose], week 4 - last dose [at pre-dose and at 2-4 hrs post dose]
First Patient First Visit: 28-Feb-2011; Last Patient Last Visit: 29-Jul-2014. The study was conducted at medical/research sites in the United States, Spain, United Kingdom, Greece, Guatemala, Hungary, Israel, and New Zealand
| Milestone | 6 to < 12 Years | ≥ 12 to ≤ 16 Years |
|---|---|---|
| Started | 27 | 128 |
| Completed | 17 | 105 |
| Not completed | 10 | 23 |
| Withdrew: Adverse event | 3 | 7 |
| Withdrew: Withdrawal by subject | 3 | 4 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 5 |
| Withdrew: Administrative | 4 | 6 |
Safety assessments consisted of reports of AEs, physical examinations, clinical laboratory test results, vital signs measurements, pulse oximetry (SpO2), and somnolence assessments. Safety variables were summarized descriptively within age group for the safety population.
| participants | 6 to < 12 Years | ≥ 12 to ≤ 16 Years |
|---|---|---|
| Serious adverse events | 5 | 22 |
| All other adverse events in ≥ 5% of patients | 13 | 60 |
Pain right now was assessed by patients aged 6 to \<12 years using the Faces of Pain Scale-Revised (FPS-R). The FPS-R is a horizontal row of 6 faces representing pain intensity, with "no hurt" at the far left and "hurts worst" at the far right; the 6 intensities are scored as 0, 2, 4, 6, 8, or 10 (the patient was not shown the numbers associated with the faces). A score of 0 means no pain, and a 10 means very much pain. Pain right now was assessed by the patient at screening; after the first dose; and, thereafter, twice daily during the AM and PM, approximately at the time of each (morning and evening) dose of oxycodone HCl CR tablets during the study treatment.
| units on a scale | 6 to < 12 Years |
|---|---|
| Baseline | 4.44 ± 3.250 |
| Average during week 1: morning | 4.11 ± 2.674 |
| Average during week 1: evening | 4.07 ± 2.695 |
| Average during week 2: morning | 3.66 ± 2.640 |
| Average during week 2: evening | 3.70 ± 2.686 |
| Average during week 3: morning | 3.64 ± 2.579 |
| Average during week 3: evening | 3.76 ± 2.669 |
| Average during week 4: morning | 3.13 ± 2.569 |
| Average during week 4: evening | 3.42 ± 2.974 |
Pain right now was assessed by patients aged ≥ 12 to ≤ 16 years using the 100-mm visual analogue scale (VAS). The 100-mm VAS is a 100-mm line with 1 end marked "no pain" and the opposite end marked as "pain as bad as it could be." The patient was asked to make a mark on that line indicating his or her level of pain. The pain right now 100-mm VAS score was defined as the distance (in mm) from the "no pain" end to the patient's mark. The scale is measured on a 100 mm line: a 0 means no pain and bigger numbers indicate more pain. Pain right now was assessed by the patient at screening; after the first dose; and, thereafter, twice daily during the AM and PM, approximately at the time of each (morning and evening) dose of oxycodone HCl CR tablets during the study treatment.
| units on a scale | ≥ 12 to ≤ 16 Years |
|---|---|
| Baseline | 44.58 ± 28.291 |
| Average during week 1: morning | 40.38 ± 24.402 |
| Average during week 1: evening | 39.24 ± 23.301 |
| Average during week 2: morning | 34.49 ± 24.980 |
| Average during week 2: evening | 33.04 ± 24.778 |
| Average during week 3: morning | 32.56 ± 25.802 |
| Average during week 3: evening | 33.46 ± 24.639 |
| Average during week 4: morning | 35.58 ± 27.177 |
| Average during week 4: evening | 35.30 ± 26.711 |
Supplemental opioid and nonopioid pain medications were permitted during the study as deemed appropriate by the investigator. The dose of supplemental analgesic medication allowed was at the discretion of the investigator and within appropriate dose ranges for age and weight.
| participants | 6 to < 12 Years | ≥ 12 to ≤ 16 Years |
|---|---|---|
| Any supplemental pain medication | 24 | 112 |
| Any opioid supplemental pain medication | 21 | 93 |
| Any nonopioid supplemental pain medication | 17 | 75 |
The PGIC rating score variable was collected on a 7-point scale ranging from 1 to 7 (where 1 = very much improved; and 7 = very much worse). The PGIC is designed to assess overall satisfaction with the treatment. The number and percent of parent/caregivers reporting each category of PGIC response at the final visit was summarized for the safety population within age group.
| participants | 6 to < 12 Years | ≥ 12 to ≤ 16 Years |
|---|---|---|
| 1 = Very much improved | 10 | 42 |
| 2 = Much improved | 8 | 51 |
| 3 = Minimally improved | 3 | 15 |
| 4 = No change | 3 | 5 |
| 5 = Minimally worse | 0 | 1 |
| 6 = Much worse | 0 | 0 |
| 7 = Very much worse | 1 | 1 |
The FDI is a validated tool used to evaluate the degree to which children have reduced physical and psychosocial functioning because of their pain difficulties in the previous 2 weeks. The FDI comprises 15 items. Responses to each item were scored using a 5-point Likert scale. The individual scores are: (0) no trouble, (1) a little trouble, (2) some trouble, (3) a lot of trouble, and (4) impossible. A total score (ranging from 0 to 60) for the 15 items was calculated, with lower scores indicating less functional disability. The FDI was performed by the parent/ caregiver.
| units on a scale | 6 to < 12 Years |
|---|---|
| Baseline | 27.1 ± 13.06 |
| Week 4 | 23.0 ± 13.32 |
The FDI is a validated tool used to evaluate the degree to which children have reduced physical and psychosocial functioning because of their pain difficulties in the previous 2 weeks. The FDI comprises 15 items. Responses to each item were scored using a 5-point Likert scale. The individual scores are: (0) no trouble, (1) a little trouble, (2) some trouble, (3) a lot of trouble, and (4) impossible. A total score (ranging from 0 to 60) for the 15 items was calculated, with lower scores indicating less functional disability. The FDI was performed by the parent/ caregiver.
| units on a scale | ≥ 12 to ≤ 16 Years |
|---|---|
| Baseline | 23.2 ± 17.47 |
| Week 4 | 20.4 ± 12.65 |
A population PK analysis using sparse plasma concentration data in pediatric patients was conducted. Empirical Bayes estimates were used to calculate individual PK parameters. PK parameters were calculated and reported for each individual patient's first and last dose. Cmax was taken as the maximum simulated oxycodone concentration over the dosing interval and Cmin was the simulated oxycodone concentration when time was equal to 12 hours. Steady-state Cmin and Cmax were derived from the accumulation ratio. The following PK parameters are presented: Cmin / Cmax (minimum / maximum concentration); Cmin,ss / Cmax,ss (Cmin / Cmax at steady state); CAVGss (average concentration at steady state).
| ng/mL | 6 to 16 Years |
|---|---|
| Cmin - first dose | 6.86 (2.69 to 23.1) |
| Cmin - last dose | 6.35 (2.34 to 22.0) |
| Cmin,ss - first dose | 7.73 (2.9 to 28.8) |
| Cmin,ss - last dose | 7.46 (2.47 to 28.9) |
| Cmax - first dose | 16.3 (7.82 to 58.2) |
| Cmax - last dose | 15.8 (7.87 to 59.5) |
| Cmax,ss - first dose | 20.9 (9.23 to 66.1) |
| Cmax,ss - last dose | 17.9 (9.46 to 68.4) |
| CAVGss - first dose | 16.1 (6.84 to 53.7) |
| CAVGss - last dose | 15.7 (6.77 to 58.9) |
A population PK analysis using sparse plasma concentration data in pediatric patients was conducted. Empirical Bayes estimates were used to calculate individual PK parameters. PK parameters were calculated and reported for each individual patient's first and last dose. First-dose area under the concentration-time curve (AUC) was derived from the accumulation ratio. For all calculations, the dosing interval was assumed to be 12 hours. The following PK parameters are presented: AUCtau (area under the concentration-time curve from time zero to time equal to dosing interval); AUCss (AUC at steady state).
| ng*hour/mL | 6 to 16 Years |
|---|---|
| AUCtau - first dose | 181 (74.2 to 562) |
| AUCtau - last dose | 158 (77.2 to 545) |
| AUCss - first dose | 194 (82.1 to 645) |
| AUCss - last dose | 188 (81.3 to 707) |
A population PK analysis using sparse plasma concentration data in pediatric patients was conducted. Empirical Bayes estimates were used to calculate individual PK parameters. PK parameters were calculated and reported for each individual patient's first and last dose.
| Hours | 6 to 16 Years |
|---|---|
| Tmax - first dose | 3.75 (2.5 to 5.75) |
| Tmax - last dose | 3.75 (2.5 to 5.75) |
A population PK analysis using sparse plasma concentration data in pediatric patients was conducted. Empirical Bayes estimates were used to calculate individual PK parameters. PK parameters were calculated and reported for each individual patient's first and last dose. The accumulation ratio is used to derive steady-state Cmin and Cmax and first-dose area under the concentration-time curve (AUCtau).
| Ratio | 6 to 16 Years |
|---|---|
| Accumulation ratio - first dose | 1.14 (1.03 to 1.40) |
| Accumulation ratio - last dose | 1.14 (1.03 to 1.42) |
Collected over Adverse events (AEs) were reported from start of study participation through the period beyond study completion.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 6 to < 12 Years | — | 5/27 (18.5%) | 13/27 (48.1%) |
| ≥ 12 to ≤ 16 Years | — | 22/128 (17.2%) | 60/128 (46.9%) |
| Event | 6 to < 12 Years | ≥ 12 to ≤ 16 Years |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 2/27 | 1/128 |
| PyrexiaGeneral disorders | 2/27 | 5/128 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/27 | 4/128 |
| Cardio-respiratory arrestCardiac disorders | 1/27 | 0/128 |
| StomatitisGastrointestinal disorders | 1/27 | 0/128 |
| Back painMusculoskeletal and connective tissue disorders | 1/27 | 0/128 |
| ComaNervous system disorders | 1/27 | 1/128 |
| ConvulsionNervous system disorders | 1/27 | 0/128 |
| Respiratory disorderRespiratory, thoracic and mediastinal disorders | 1/27 | 0/128 |
| VomitingGastrointestinal disorders | 0/27 | 2/128 |
| Event | 6 to < 12 Years | ≥ 12 to ≤ 16 Years |
|---|---|---|
| VomitingGastrointestinal disorders | 6/27 | 26/128 |
| PyrexiaGeneral disorders | 5/27 | 8/128 |
| NauseaGastrointestinal disorders | 3/27 | 20/128 |
| ConstipationGastrointestinal disorders | 4/27 | 12/128 |
| HeadacheNervous system disorders | 3/27 | 17/128 |
| PruritusSkin and subcutaneous tissue disorders | 3/27 | 7/128 |
| DizzinessNervous system disorders | 0/27 | 11/128 |
The safety population was the group of patients who received at least 1 dose of study drug during the study.
| Age, Continuous(years) | 6 to < 12 Years | ≥ 12 to ≤ 16 Years | Total |
|---|---|---|---|
| Mean | 9.6 ± 1.65 | 14.5 ± 1.34 | 13.7 ± 2.33 |
| Sex: Female, Male(Participants) | 6 to < 12 Years | ≥ 12 to ≤ 16 Years | Total |
|---|---|---|---|
| Female | 14 | 75 | 89 |
| Male | 13 | 53 | 66 |
| Race/Ethnicity, Customized(participants) | 6 to < 12 Years | ≥ 12 to ≤ 16 Years | Total |
|---|---|---|---|
| White | 20 | 88 | 108 |
| Black or African American | 7 | 31 | 38 |
| Asian | 0 | 1 | 1 |
| Other | 0 | 8 | 8 |
The record gives a start of Nov 2010, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxycodone